Maternal serum biomarkers for risk assessment in gestational diabetes. A potential universal screening test to predict GDM status

Srinivasa R. Nagalla, Caryn K. Snyder, John E. Michaels, Mary J. Laughlin, Charles Roberts, Madhuri Balaji, V. Balaji, V. Seshiah, Paturi V. Rao

    Research output: Contribution to journalArticle

    11 Scopus citations


    The prevalence of gestational diabetes mellitus (GDM) is increasing because of the worldwide obesity/diabetes epidemic. The complications of untreated GDM affect both the mother and baby and include complications during pregnancy as well as increased risk of subsequent type-2 diabetes in mothers and offspring. Standard tests for hyperglycemia in diabetes, such as fasting glucose and hemoglobin (HbA1c), are currently not recommended for GDM screening. Instead, an oral glucose tolerance test is specified, which is invasive, time-consuming, and not easily accessible to many at-risk populations. In this study, we describe a multi-analyte maternal serum profile test that incorporates novel glycoprotein biomarkers and previously described GDM-associated markers. In screening for GDM by multi-analyte panel, the detection rate was 87% at a false-positive rate of 1%.

    Original languageEnglish (US)
    Pages (from-to)155-159
    Number of pages5
    JournalIndian Journal of Endocrinology and Metabolism
    Issue number1
    Publication statusPublished - Jan 1 2015



    • Gestational diabetes
    • glycosylated fibronectin
    • maternal serum biomarker

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Cite this